Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 20,886 |
|
|||||
| News | - | ||||||
| Day High | 1.80 | Low High |
|||||
| Day Low | 1.715 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| eFFECTOR Therapeutics Inc | EFTR | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.065 | -3.65% | 1.715 | 10:35:33 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.80 | 1.715 | 1.80 | 1.78 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 223 | 20,886 | $ 1.76 | $ 36,754 | - | 1.69 - 37.00 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 10:35:30 | 2 | $ 1.7194 | USD |
eFFECTOR Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 5.24M | 3.00M | - | 0 | -35.81M | -11.95 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
eFFECTOR Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical EFTR Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.27 | 2.27 | 1.69 | 1.95 | 242,078 | -0.555 | -24.45% |
| 1 Month | 12.58 | 16.882 | 1.69 | 4.10 | 901,585 | -10.87 | -86.37% |
| 3 Months | 9.09 | 17.75 | 1.69 | 6.31 | 396,315 | -7.38 | -81.13% |
| 6 Months | 14.1925 | 17.90 | 1.69 | 11.75 | 1,241,820 | -12.48 | -87.92% |
| 1 Year | 9.50 | 37.00 | 1.69 | 16.58 | 1,265,042 | -7.79 | -81.95% |
| 3 Years | 475.00 | 1,010.50 | 1.69 | 117.69 | 795,348 | -473.29 | -99.64% |
| 5 Years | 475.00 | 1,010.50 | 1.69 | 117.69 | 795,348 | -473.29 | -99.64% |
eFFECTOR Therapeutics Description
| eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK1/2 that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer (NSCLC). The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 1/2 clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. The company was founded in 2012 and is headquartered in San Diego, California. |
